June 8, 2017 / 11:29 AM / in 4 months

BRIEF-Medicenna's Immunotherapy phase 2B trial underway using Brainlab drug delivery technology

June 8 (Reuters) - Medicenna Therapeutics Corp

* Medicenna’s Immunotherapy phase 2B trial underway using Brainlab drug delivery technology

* Medicenna Therapeutics - current phase 2B clinical trial plans to enroll 43 adult patients with RGB at leading brain cancer centers in United States Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below